Characterization of Mouse Tissue Kallikrein 5

Sanath Rajapakse¹,², Katsueki Ogiwara¹, Noriko Yamano³, Atsushi Kimura¹,
Kensaku Hirata³, Sumio Takahashi³, Takayuki Takahashi¹,*

¹Laboratory of Molecular and Cellular Interactions, Faculty of Advanced Life Science,
Hokkaido University, Sapporo, 060-0810 Japan

²Department of Molecular Biology and Biotechnology, Faculty of Science, University
of Peradeniya, Peradeniya, Sri Lanka

³Department of Biology, Faculty of Science, Okayama University, Okayama, Tsushima,
Okayama 700-8530, Japan

Abbreviated form of title: Mouse Tissue Kallikrein 5

*Corresponding author: Takayuki Takahashi, Laboratory of Molecular and Cellular
Interactions, Faculty of Advanced Life Science, Hokkaido University, Sapporo,
060-0810 Japan

Tel: 81-11-706-2748; Fax: 81-11-706-4851; E-mail: ttakaha@sci.hokudai.ac.jp

Section for review: Biochemistry
Abstract

Mouse tissue kallikreins (Klks) are members of a large multigene family consisting of 37 genes, 26 of which can code for functional proteins. Mouse tissue kallikrein 5 (Klk5) has long been thought to be one of these functional genes, but isolation and characterization studies of this gene product, mK5, have not been done before. In the present study, active recombinant mK5 was prepared using an Escherichia coli expression system followed by column chromatographies. Using the purified mK5 sample, the biochemical and enzymic properties were determined. mK5 had trypsin-like activity for Arg at the P1 position, and its activity was inhibited by typical serine protease inhibitors. Gelatin, fibronectin, collagen type IV, and high-molecular-weight kininogen were degraded by mK5. In addition, mK5 degraded insulin-like growth factor binding protein-3. The present data suggest that mK5 may be implicated in the process of extracellular matrix remodeling.

Key words: mouse, protease, kallikrein 5, recombinant enzyme, characterization
INTRODUCTION

Mouse tissue kallikreins (*Klks*) are members of a large multigene family located as a gene cluster in cytogenic region B2 on the mouse chromosome (Diamandis *et al*., 2004; Olsson *et al*., 2004). Previous studies suggest that individual *Klk* gene products (mKs) are involved in many vital functions, such as kinin production, coagulation and fibrinolysis, activation and/or inactivation of peptide hormones, regulation of growth factors, and extracellular matrix protein turnover (Margolius, 1998). It is now established that the mouse has 37 *Klk* genes, 26 of which can code for functional proteins (Diamandis *et al*., 2004; Olsson *et al*., 2004). However, only about half of the 26 genes have been characterized to date by molecular biological and biochemical approaches. Mouse tissue kallikrein 5 (*Klk5*) is one of the as-yet-uncharacterized *Klk* genes. At present, the nucleotide sequence is the only available information for this particular gene, and studies at the protein level are required to determine its biological role.

In our previous studies, the expression of *Klk21* (Matsui and Takahashi, 2001), *Klk24* (Matsui *et al*., 2005a, b) and *Klk27* (Matsui *et al*., 2000) in the testis, and their implications in the function of this male reproductive organ were documented. In an attempt to examine whether or not the *Klk* genes described above are expressed in other mouse tissues using RT-PCR, we happened to isolate a *Klk5* fragment from the uterus, suggesting that mK5 may play a role in the female reproductive system. To establish a basis for further physiological studies of mK5, active recombinant mK5 was prepared for biochemical characterization. The present data suggest that mK5 may play a role in various biological processes.
MATERIALS AND METHODS

Expression vector construction

The expression vector for mK5 was prepared basically in the same way as for mK21 (Matsui and Takahashi, 2001). Briefly, a cDNA corresponding to the amino acid residues 18-261, including the pro-enzyme region of the Klk5 gene (DDBJ/EMBL/GenBank databases NM 008456), was inserted into the EcoRI and HindIII sites of pET30a (Novagen, Madison, WI). A sense primer 5’-CCGGAATTCGCACCTCCAGTCCAA-3’, which includes the EcoRI site, and an antisense primer 5’-CCCAAGCTTTCAGGCATTTTTAGCTAT-3’, which includes the HindIII site, were synthesized. PCR using KOD plus DNA polymerase (Toyobo, Osaka, Japan) was performed using mouse skeletal muscle cDNA as a template with the above primers to create EcoRI sites at the 5’ ends and HindIII sites at the 3’ ends. The PCR conditions were as follows: 3 min at 94°C for heating, followed by 30 cycles of 30 sec at 94°C for denaturing, 30 sec at 55°C for annealing and 1 min at 68°C for extension. The reaction product was sequentially digested with EcoRI and HindIII, then gel purified and ligated in frame between the EcoRI and HindIII sites of pET30a. The orientation and sequence of the cDNA in the vector plasmid were confirmed by DNA sequencing.

Production and purification of active mK5

The ligated vector (pET30a-mK5) was transformed to E. coli strain BL21. The cells were grown at 37°C, induced with isopropyl-1-thio-β-D-galactoside, harvested by centrifugation, and lysed by freeze-thawing. The samples were washed twice with 0.5%
Triton X-100, solubilized in 50 mM Tris-HCl (pH 7.8) containing 6 M urea and 0.5 M NaCl, and incubated for 12 h in the same buffer containing 6 M urea and 0.5 M NaCl at room temperature. The solubilized samples were fractionated on a Ni\textsuperscript{2+}-chelate column (5 ml volume) (Novagen) previously equilibrated with 50 mM Tris-HCl (pH 7.8) containing 0.5 M NaCl and 6 M urea (Matsui and Takahashi, 2001). Elution was conducted with 50 mM histidine in the same buffer containing 0.5 M NaCl and 6 M urea. Eluted protein was extensively dialyzed against 50 mM Tris-HCl (pH 8.0). The protein thus prepared was a fusion protein containing 51 extra amino acids, all of which originated from the plasmid sequence, at the N-terminus, in addition to the complete pro-mK5 sequence. This fusion protein was then incubated in 50 mM Tris-HCl (pH 8.0) with trypsin-Sepharose 4B, and the resulting active mK5 enzyme preparation was further purified by column chromatography on a Resource Q column (1 ml bed volume) (AKTA FPLC system) previously equilibrated with 50 mM Tris-HCl (pH 8.0). The retained materials were eluted with a linear gradient of 0-0.5 M NaCl in the same buffer. One milliliter fractions were collected and the enzyme activity of mK5 was assayed with a 4-methylcoumaryl-7-amide (MCA)-containing synthetic substrate, Pro-Phe-Arg-MCA (Peptide Institute, Osaka, Japan).

**Enzyme activity**

Recombinant mK5 activity was determined according to the method of Barrett (1980) with a slight modification. Briefly, the reaction solutions contained 0.1 M Tris-HCl buffer (pH 8.0), 0.1 mM MCA substrate, and enzyme sample in a final volume of 0.5 ml. The reaction was initiated by the addition of the substrate and stopped by the addition of 2.5 ml of 30 mM sodium acetate buffer (pH 4.3) containing 100 mM
monochloroacetic acid. The release of fluorophore 7-amino-4-methylcoumarin (AMC) was measured by spectrofluorometry using an excitation wavelength of 370 nm and an emission wavelength of 460 nm.

**Kinetic parameters**

Kinetic parameters were determined for various MCA substrates. Initial velocities, extrapolated from the plot of product versus time, were transformed into double-reciprocal plots. Maximum velocities ($V_{\text{max}}$), $K_m$, and $k_{\text{cat}}$ values were obtained from the intercepts of these plots.

The active mK5 concentration was determined using the active site titrant $p$-nitrophenyl-$p'$-guanidinobenzoate HCl according to the method of Chase and Shaw (1967).

**Inhibition of mK5 by protease inhibitors**

Active mK5 (0.1 μg) was pre-incubated with different concentrations of protease inhibitors at 37°C for 15 min in 0.1 M Tris-HCl buffer (pH 8.0). After addition of 0.1 mM Pro-Phe-Arg-MCA, the residual enzyme activity was measured.

**Degradation of protein substrates by mK5**

Gelatin zymography was performed according to the method previously described (Heussen and Dowdle, 1980). Briefly, mK5 was electrophoresed on 12% SDS-PAGE gels containing 1 mg/ml type A porcine skin gelatin (Sigma, St. Louis, MO) under non-reducing conditions. After electrophoresis, gels were washed twice in 2.5% Triton X-100 for 30 min, and then incubated with shaking in 0.1 M glycine-NaOH (pH 8.3) for
18 h at 37°C. The gels were stained with 0.25% Coomassie Brilliant Blue to visualize zones of lysis.

Casein (Wako Pure Chemical Industries Ltd., Osaka, Japan) was added to mK5 at a ratio of 10:1 (w/w) in 50 mM Tris-HCl buffer (pH 8.0), and the mixtures were incubated at 37°C. Aliquots removed at different time points were analyzed by SDS-PAGE and Coomassie Brilliant Blue staining.

Degradation of fibronectin and laminin was performed as previously described (Rajapakse et al., 2005). Briefly, 4 μg of human plasma fibronectin (Chemicon, Temecula, CA), and 4 μg mouse laminin (Biomedical Technologies Inc., Stoughton, MA) were each incubated at 37°C in 20 μl of 50 mM Tris-HCl buffer (pH 8.0) with 400 ng of mK5 for 18 h. The reactions were stopped by the addition of SDS sample buffer, and the reaction mixtures were boiled and subjected to SDS-PAGE. After electrophoresis, gels were stained with 0.25% Coomassie Brilliant Blue.

Effect of mK5 on collagen types I and IV was examined according to the method described previously (Ogiwara et al., 2005). Briefly, twenty-five micrograms of FITC-conjugated bovine collagen types I and IV (Yagai Corporation, Yamagata, Japan) were incubated with 500 ng of mK5 at 33°C for 16 h in 100 μl of 50 mM Tris-HCl buffer (pH 8.0). After incubation, the reactions were terminated by adding 300 μl of stopping reagent (42% ethanol, 50 mM Tris-HCl (pH 9.5), and 0.2 M NaCl). Samples were incubated on ice for 10 min, and then centrifuged at 10,000 ×g for 10 min. Aliquots of the resulting supernatants were diluted to a volume of 3.0 ml with distilled water, and the fluorescence was measured at an excitation wavelength of 459 nm and emission wavelength of 520 nm.

Five μg of purified high-molecular-weight kininogen (Calbiochem, La Jolla, CA)
was incubated with 500 ng of active mK5 in 0.1 M Tris-HCl buffer, pH 8.0 at 37 °C. Aliquots were removed at various time intervals, the reactions were stopped by the addition of SDS sample buffer, and the samples were analyzed by SDS-PAGE followed by Coomassie Brilliant Blue staining.

Twenty-five ng of human insulin-like growth factor binding protein-3 (IGFBP-3) (Genzyme, Cambridge, MA) was incubated with 10-80 ng of the recombinant mK5 at 37 °C in 20 μl of 0.1 M Tris-HCl (pH 8.0). The reaction was stopped by the addition of SDS sample buffer. The reaction mixtures were boiled, separated on 12% SDS-PAGE, and transferred to a polyvinylidene difluoride transfer (PVDF) membrane (Millipore). The blotted membrane was incubated with goat anti-human IGFBP-3 (Santa Cruz Biotechnology Inc., Santa Cruz, CA) at a 1:1000 dilution and subsequently with donkey anti-sheep/goat IgG (Amersham Pharmacia, Biotech, Tokyo, Japan). Immunoreactive signals were detected using an ECL Western blot detection kit (Amersham Biosciences, Buckinghamshire, England) according to the protocol provided by the manufacturer.

Action of mK5 on human single-chain tissue-type plasminogen activator (American Diagnostica Inc., Greenwich, CT) was examined according to the method described previously (Ohnishi et al., 2004).

RESULTS

Preparation of mK5

In order to obtain a Klk5 cDNA encoding mK5, we conducted RT-PCR using the primer set described in the Materials and methods section. Total RNAs isolated from salivary glands and skeletal muscles of adult mice were used as templates. PCR products amplified with the RNAs were found to contain two mouse Klk species, Klk1
and Klk5, by sequence analyses. In the present study, a full-length cDNA isolated from the mouse skeletal muscle was used for the following experiment.

The recombinant protein was expressed in *E. coli* (BL21) transformed with the vector pET30a-mK5, and the enzyme was purified as described in the Materials and Methods section. SDS-PAGE analysis of the active enzyme sample eluted from a Resource Q column gave a single polypeptide band. The apparent molecular masses were estimated to be 28.5 kDa under reducing conditions and 25.5 kDa under non-reducing conditions (Fig. 1).

**Enzymatic properties of mK5**

The enzyme showed no detectable activity loss for at least 2 months when stored at -20°C. The electrophoretic pattern did not change under such storage conditions.

The enzyme activity of the recombinant mK5 was measured at various pHs using Pro-Phe-Arg-MCA as substrate. The activity was detected at a pH range of 7-10, and the optimum pH was 9.5

Fluorogenic peptide substrates with the AMC-leaving group were tested for mK5 to determine its kinetic constants (Table 1). Pro-Phe-Arg-MCA was very rapidly hydrolyzed. Other substrates, i.e., Z-Phe-Arg-MCA, Z-Leu-Arg-MCA, Pyr-Gly-Arg-MCA and Z-Val-Val-Arg-MCA, were hydrolyzed by mK5 to a lesser extent. Among the substrates hydrolyzed, the highest $k_{cat}$ value and lowest $K_m$ value were obtained with the substrate Pro-Phe-Arg-MCA. Substrates containing Lys at the P1 position were not hydrolyzed. The enzyme showed no activity for synthetic substrates containing tetrapeptides tested.

The enzyme activity of mK5 was strongly inhibited by diisopropyl fluorophosphate
(DFP) and leupeptin (Table 2). A slight inhibition was observed with aprotinin. None of the other inhibitors tested showed significant inhibition of mK5 activity. Assays of two different batches of enzyme preparation gave the same results.

The results described above suggest that mK5 is a serine protease with strict trypsin-like cleavage specificity.

**Hydrolysis of protein substrates by mK5**

Zymographic analysis using gelatin was conducted for mK5. A single lytic band at a position corresponding to Mr=25.5 kDa was seen (Fig. 2A). Incubation of intact fibronectin (Mr=220 kDa) with mK5 generated two degradation products (Mr=200 and 190 kDa) (Fig. 2B). mK5 cleaved collagen type IV but not type I collagen (Fig. 2C). High-molecular-weight kininogen was a substrate for mK5 (Fig. 2D). Casein and laminin were resistant to mK5 (data not shown). mK5 did not convert the single-chain tissue-type plasminogen activator to the two-chain form of the enzyme (data not shown).

The effect of mK5 on IGFBP-3 was examined. The enzyme degraded the intact protein (Mr=41 kDa) in a time-dependent manner as well as in a dose-dependent manner with concomitant production of 31 and 17 kDa fragments (Fig. 3A and 3B).

**DISCUSSION**

The mouse *Klk5* gene was previously identified as a member of the tissue kallikrein multigene family located on chromosome 7 (Mason *et al.*, 1983). Based on the nucleotide sequence data of *Klk5*, the gene product mK5 has been postulated to be a functional protease. However, little information on this protein is currently available. To
our knowledge, there has been only one study on this protein, which dealt with the mRNA expression of the kallikrein in the mouse uterus and decidua (Chan et al., 1999). Since our laboratory is interested in the roles of proteases, including tissue kallikreins, in uterine function, we decided to characterize mK5 biochemically.

mK5 hydrolyzed the synthetic substrate Pro-Phe-Arg-MCA with a $k_{cat}/K_m$ value (mM$^{-1}$·min$^{-1}$) of 1300, which was approximately 25 times greater than the values for the other substrates tested, indicating that Pro-Phe-Arg-MCA was the best substrate. mK21 (Matsui and Takahashi, 2001) and mK24 (Matsui et al., 2005a, b), both of which have been recently characterized in this laboratory, showed strong activity for this substrate. Like mK21 and mK24, mK5 does not cleave Lys-X bonds at all. Table 1 indicates that mK5 is highly specific for the hydrolysis of peptide bonds at the carboxyl side of arginine residues.

The serine protease nature of mK5 was evident based on the strong inhibitions with the protease inhibitors DFP and leupeptin. However, some other typical serine protease inhibitors, such as SBTI and benzamidine, did not affect mK5 activity. The resistance of mK5 to the above two inhibitors was rather surprising, because the previously characterized mK21 and mK24 were substantially inhibited by these compounds (Matsui and Takahashi, 2001; Matsui et al., 2005a, b). In this regard, we should note our recent observation that mK1 (true mouse tissue kallikrein) is also resistant to SBTI and benzamidine (our unpublished data). The fact that mK5 resembles mK1 with respect to its behaviors toward protease inhibitors may indicate that mK5 and mK1 have highly similar protein structures. Indeed, recent studies by Olsson and Lundwall (2002) on the organization and evolution of mouse Klk genes have established that Klk1 (coding mK1) and Klk5 (coding mK5) are located alongside each other, and that they are structurally
closest among the mouse Klk genes.

The present study clearly demonstrates that mK5 hydrolyzes various proteins, including ECM proteins (gelatin, fibronectin, and collagen type IV), high-molecular-weight kininogen, and IGFBP-3. These facts suggest that mK5 may play roles in a variety of biological processes.

Fibronectin is an adhesive cell-surface protein important for the interaction of cells with adjacent cells or ECM components. Degradation of this protein causes the disintegration of local ECM environments, leading to increased mobility of the cells residing in the ECM. Such an event is particularly important in the process of ECM remodeling. The present finding of mK5’s ability to degrade fibronectin indicates that the protease may be involved in the ECM remodeling process. The finding that mK5 showed collagenolytic activity for collagen type IV is consistent with this idea.

Another interesting finding is that mK5 cleaves IGFBP-3. IGFBP-3 is a member of a family of peptides which have a strong affinity with IGF-I and IGF-II, and plays an inhibitory role for the activity of IGF. It is generally believed that IGFBP proteolysis can reverse the inhibition due to the increased concentration of free IGFs near their receptor. The involvement of many proteases in IGFBP proteolysis has been reported (Firth and Baxter, 2002). Our data suggest that mK5 is another candidate protease for the degradation of IGFBP-3. IGFBP-3 hydrolysis by mK5 produced two major polypeptides (31 and 17 kDa), pointing to a cleavage at a single peptide bond by mK5. We previously reported that IGFBP-3 is cleaved by mK21 (Matsui and Takahashi, 2001). Interestingly, the hydrolysis patterns of IGFBP-3 appear to be the same between mK21 and mK5. The human IGFBP-3 preparation used in this study contains various sites susceptible to proteases. Because mK5 specifically cleaved Arg-X bonds and because
the IGFBP-3 is reported to be hydrolyzed by many trypsin-like proteases at \( \text{Arg}^{97}-\text{Ala}^{98} \), we tentatively suggest this peptide bond may be the site of cleavage. However, the validity of this assumption needs to be established by future experiments. In short, mK5 could be a protease regulating the activity of IGFs through the degradation of IGFBP-3.

In this study, we observed that mK5 hydrolyzes high-molecular-weight kininogen. However, the biological meaning of this activity is unknown at present.

In summary, this report describes for the first time the characterization of recombinant mK5, which is encoded by an as-yet-unexamined mouse tissue kallikrein gene (\( Klk5 \)). The serine protease nature of mK5 with cleavage specificity for Arg-X bonds was demonstrated. Our data suggest that mK5 may play a role in the ECM remodeling process, and should be helpful for future physiological studies of mK5.

ACKNOWLEDGMENTS

This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan: nos. 14204079 (T.T.) and 13440247 (S.T.).
REFERENCES
Matsui H, Takahashi T (2001) Mouse testicular Leydig cells express Klk21, a tissue
kallikrein that cleaves fibronectin and IGF-binding protein-3. Endocrinology 142:4918-4929


**Figure Legends**

Fig. 1. Purity of purified recombinant mK5.

Purified active mK5 was subjected to SDS-PAGE analysis under reducing (lane 2) and non-reducing (lane 3) conditions and visualized by Coomassie Brilliant Blue R-250 staining. Lane 1, molecular mass standards (kDa).

Fig. 2. Degradation of extracellular matrix and plasma proteins

(A) Gelatin zymography of mK5. Purified mK5 (0.5 μg) was loaded on SDS-PAGE gels containing 1 mg/ml gelatin. Electrophoresis was conducted under non-reducing conditions. An arrow indicates the gelatinolytic activity of mK5. Molecular weight markers (kDa) of the standard proteins are indicated to the left. (B) Effect of mK5 on fibronectin. Human fibronectin was separately incubated without (lane 2) or with (lane 3) mK5 for 18 h at 37°C and was subjected to SDS-PAGE under reducing conditions followed by Coomassie Brilliant Blue R-250 staining. Lane 1, molecular mass standards (kDa). An arrow and star indicate intact and degraded form of fibronectin, respectively. (C) Effect of mK5 on collagens. FITC-conjugated collagens type I and type IV were incubated without mK5 (-mK5) and with mK5 (+mK5) for 18 h at 33°C, and the fluorescence intensities of the supernatants were measured. Values of means ± SEM from three separate experiments are shown. (D) Effect of mK5 on high-molecular-weight kininogen. The kininogen was incubated with mK5 for 0 (lane 2), 0.5 (lane 3), 1 (lane 4), 2 (lane 5), 4 (lane 6), or 6 h (lane 7) at 37°C and was subjected to SDS-PAGE under reducing conditions followed by Coomassie Brilliant Blue R-250 staining. Lane 8, incubation for 6 h without mK5. Lane 1, molecular mass standards (kDa). An arrow and stars indicate intact and degraded form of the kininogen,
respectively.

Fig.3. Action of mK5 toward human recombinant IGFBP-3.

(A) Human IGFBP-3 (25 ng) was incubated at 37°C with the indicated amounts of mK5 in 20 μl 100 mM Tris-HCl (pH 8.0) for 2 h and was subjected to SDS-PAGE followed by Western blot analysis using anti IGFBP-3 antibody. (B) IGFBP-3 (25 ng) was incubated at 37°C with mK5 (40 ng) for the periods indicated at the top of the figure and was subjected to SDS-PAGE/Western blot analysis as described in (A). In both panels, molecular weight markers (kDa) of standard proteins are indicated to the left and intact IGFBP-3 and its degraded products (31 and 17 kDa) to the right.
### Table 1

Kinetic parameters of mK5 as measured on MCA-containing substrates

<table>
<thead>
<tr>
<th>Substrates</th>
<th>( V_{\text{max}} )</th>
<th>( K_m )</th>
<th>( k_{\text{cat}} )</th>
<th>( k_{\text{cat}}/K_m )</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>( \mu\text{mol/min/mg} )</td>
<td>( \text{mM} )</td>
<td>( \text{min}^{-1} )</td>
<td>( \text{mM}^{-1} \cdot \text{min}^{-1} )</td>
</tr>
<tr>
<td>Pro-Phe-Arg-MCA</td>
<td>1.5</td>
<td>0.03</td>
<td>39</td>
<td>1300</td>
</tr>
<tr>
<td>Z-Phe-Arg-MCA</td>
<td>0.3</td>
<td>0.13</td>
<td>7.6</td>
<td>58</td>
</tr>
<tr>
<td>Z-Leu-Arg-MCA</td>
<td>0.1</td>
<td>0.05</td>
<td>2.7</td>
<td>54</td>
</tr>
<tr>
<td>Pyr-Gly-Arg-MCA</td>
<td>0.1</td>
<td>0.03</td>
<td>1.6</td>
<td>53</td>
</tr>
<tr>
<td>Z-Val-Val-Arg-MCA</td>
<td>0.2</td>
<td>0.11</td>
<td>4.7</td>
<td>43</td>
</tr>
<tr>
<td>Boc-Val-Leu-Lys-MCA</td>
<td>ND</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boc-Glu-Lys-Lys-MCA</td>
<td>ND</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suc-Leu-Leu-Val-Tyr-MCA</td>
<td>ND</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ac-Ile-Glu-Thr-Asp-MCA</td>
<td>ND</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suc-Ala-Ala-Pro-Phe-MCA</td>
<td>ND</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Z, benzyloxycarbonyl; Pyr, pyroglutamyl; Boc, tert-butyloxycarbonyl; Suc, succinyl; Ac, acetyl; ND, not determined because of no significant activity.
Table 2

Effects of protease inhibitors on mK5 activity

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>Concentration</th>
<th>Inhibition (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DFP</td>
<td>2.0 mM</td>
<td>87</td>
</tr>
<tr>
<td>Leupeptin</td>
<td>0.1 mM</td>
<td>70</td>
</tr>
<tr>
<td>Aprotinin</td>
<td>0.1 mg/ml</td>
<td>34</td>
</tr>
<tr>
<td>Antipain</td>
<td>0.2 mM</td>
<td>13</td>
</tr>
<tr>
<td>SBTI</td>
<td>0.1 mg/ml</td>
<td>0</td>
</tr>
<tr>
<td>Benzamidine</td>
<td>1.0 mM</td>
<td>0</td>
</tr>
<tr>
<td>E-64</td>
<td>0.5 mM</td>
<td>12</td>
</tr>
<tr>
<td>o-Phenanthroline</td>
<td>2.0 mM</td>
<td>10</td>
</tr>
<tr>
<td>Pepstatin</td>
<td>0.1 mM</td>
<td>0</td>
</tr>
<tr>
<td>TPCK</td>
<td>0.2 mM</td>
<td>14</td>
</tr>
<tr>
<td>TLCK</td>
<td>0.2 mM</td>
<td>7</td>
</tr>
<tr>
<td>EDTA</td>
<td>0.1 mM</td>
<td>0</td>
</tr>
<tr>
<td>Chymostatin</td>
<td>0.2 mM</td>
<td>0</td>
</tr>
</tbody>
</table>

DFP, diisopropyl fluorophosphate; SBTI, soybean trypsin inhibitor; TPCK, *N*<sub>α</sub>-p-tosyl-L-phenylalanine chloromethyl ketone; TLCK, *N*<sub>α</sub>-p-tosyl-L-lysine chloromethyl ketone; EDTA, ethylenediamine tetraacetic acid
Figure 1
Rajapakse et al.
Figure 2
Rajapakse et al.
Figure 3
Rajapakse et al.